Bisfosfonatbehandling kan orsaka stressfraktur. Men behandlingsnyttan är betydligt större än risken
Sammanfattning
Bisphosphonates increase BMD by suppressing osteoclastic activity. Treating postmenopausal osteoporosis with alendronate is well established since FDA approval 1995. However treatment with bisphophonates for 3-5 years has been associated with stress fractures of the femoral shaft. Patients on bisphophonate-treatment with thigh or groin pain should be examined with radiographs. If cortical thickening of the proximal femur is demonstrated, alendronate treatment should be stopped.